Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 26026 results found since Jan 2013.

Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
CONCLUSIONS: Improvement of local tumor control following androgen deprivation combined with VTP provides the rationale and preliminary protocol parameters for clinical trials in patients presented with locally advanced PCa. PMID: 29463549 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 20, 2018 Category: Cancer & Oncology Authors: Kim K, Watson PA, Lebdai S, Jebiwott S, Somma A, La Rosa SP, Mehta D, Murray KS, Lilja HG, Ulmert D, Monette S, Scherz AJ, Coleman J Tags: Clin Cancer Res Source Type: research

Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
CONCLUSIONS: Results support the efficacy, safety, and QoL associated with padeliporfin focal treatment for low/intermediate risk localized PCa. PMID: 29699883 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - April 23, 2018 Category: Urology & Nephrology Authors: Rodriguez-Rivera JA, Rodriguez-Lay R, Zegarra-Montes L, Benzaghou F, Gaillac B, Azzouzi AR, Reis LO, Palma P Tags: Actas Urol Esp Source Type: research

A chemiluminescent dual-aptasensor capable of simultaneously quantifying prostate specific antigen and vascular endothelial growth factor.
Abstract An aptasensor with guanine chemiluminescence detection was developed for the early diagnosis of prostate cancer with the simultaneous quantifications of prostate specific antigen (PSA) and vascular endothelial growth factor (VEGF). A PSA DNA aptamer conjugated with Texas Red emits red light in guanine chemiluminescence reaction, whereas a VEGF DNA aptamer conjugated with 6-FAM emits green light. The PSA and VEGF aptamers immobilized on the surface of paramagnetic beads mixed with a sample were incubated for 30 min. After the incubation, PSA and VEGF bound with PSA and VEGF aptamers were simultaneously q...
Source: Analytical Biochemistry - October 24, 2018 Category: Biochemistry Authors: Chong J, Chong H, Lee JH Tags: Anal Biochem Source Type: research

Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: Results of prostate cancer Latin-American multicenter study
ConclusionsResults support the efficacy, safety, and QoL associated with padeliporfin focal treatment for low/intermediate risk localized PCa.ResumenObjetivosExplorar la proporción de pacientes con cáncer de próstata localizado (CaP) de mayor riesgo que se convertiría en una biopsia negativa con seguridad 12 meses después de la terapia focal no térmica con terapia fotodinámica dirigida vascular de padeliporfina (TFV).MétodosEstudio multicéntrico en un escenario de antígeno prostático específico (PSA) ≤ 20 ng/ml y patrón 3 de Gleason de volúmenes objetivo de CaP variable o patrón 4 de Gleason...
Source: Actas Urologicas Espanolas - November 11, 2018 Category: Urology & Nephrology Source Type: research

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
Conclusion.Neoadjuvant pazopanib therapy did not alter the premetastatic niche; however, treatment targeting vascular endothelial growth factor (VEGF) in the preoperative period was safe and feasible, which may open up the avenue to investigate novel combinatorial regimens, including a VEGF inhibitor in combination with immune checkpoint inhibitor in this setting.
Source: The Oncologist - December 13, 2018 Category: Cancer & Oncology Authors: Benjamin L. Maughan, Sumanta K. Pal, David Gill, Kenneth Boucher, Christopher Martin, Meghan Salgia, Roberto Nussenzveig, Ting Liu, Josiah L. Hawks, Julia Batten, Gayatri Nachaegari, Robert Stephenson, William Lowrance, Jeremy Jones, Christopher Dechet, N Tags: Prostate, Chinese Edition, Clinical Trial Results Source Type: research

Lymphedema-associated comorbidities and treatment gap
ConclusionsTo our knowledge, this is the largest study to date detailing the comorbidities associated with LE and LE treatment rates within each. Our findings suggest that a sizable proportion of cancer-related LE patients do not receive appropriate treatment. Furthermore, this study highlights the role of advanced venous disease as an LE comorbidity that is frequently untreated and its associated gap in treatment.
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - June 25, 2019 Category: Surgery Source Type: research

Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
Abstract Vascular-targeted photodynamic therapy (VTP) using padeliporfin is currently assessed as a low-risk prostate cancer (LRPCa) treatment. The aim of this study was to assess erectile function outcomes of VTP for LRPCa treatment. We prospectively included all patients treated with VTP for LRPCa. The primary endpoint was the post-treatment International Index of Erectile Function score (IIEF5 score) evolution (at 6 months, 12 months, and then every year for 5 years). Secondary endpoints were the need of erectile dysfunction (ED) treatment and its efficacy. Eighty-two men were included. The median follow-up was...
Source: Asian Journal of Andrology - January 13, 2020 Category: Urology & Nephrology Authors: Chelly S, Maulaz P, Bigot P, Azzouzi AR, Lebdai S Tags: Asian J Androl Source Type: research

Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Abstract Prostate Cancer is the second cause of cancer-related death in men and development of metastatic castration-resistant prostate cancer (mCRPC) is the major reason for its high mortality rate. Despite various treatments, all patients succumb to resistant disease, suggesting that there is a pressing need for novel and more efficacious treatments. Members of the vascular endothelial growth factor (VEGF) family play key roles in the tumorigenesis of mCRPC, indicating that VEGF-targeted therapies may have potential anti-tumor efficacy in this malignancy. However, due to compensatory activation of other family m...
Source: European Journal of Pharmacology - June 24, 2020 Category: Drugs & Pharmacology Authors: Momeny M, Sankanian G, Hamzehlou S, Yousefi H, Esmaeili F, Alishahi Z, Karimi B, Zandi Z, Shamsaiegahkani S, Sabourinejad Z, Kashani B, Nasrollahzadeh A, Mousavipak SH, Mousavi SA, Ghaffari SH Tags: Eur J Pharmacol Source Type: research

Preclinical Quantification of Prostate Cancer-Associated Vascular Alterations in the Bone Microenvironment in vivo
Discussion: The increase in blood flow velocity could be a specific characteristic of prostate cancer or the bone microenvironment.Eur Surg Res
Source: European Surgical Research - February 24, 2021 Category: Surgery Source Type: research

Molecules, Vol. 26, Pages 3744: Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model
Conclusions: Our findings suggest that VTP synergizes with PD-1 blockade and OX40 agonist to promote strong antitumor immune responses, yielding therapeutic efficacy in an animal model of urothelial cancer.
Source: Molecules - June 19, 2021 Category: Chemistry Authors: Ricardo G. Alvim Petrina Georgala Lucas Nogueira Alexander J. Somma Karan Nagar Jasmine Thomas Laura Alvim Amelia Riegel Christopher Hughes Jie Chen Augusto B. Reis Souhil Lebdai Avigdor Scherz Steven Zanganeh Rui Gardner Kwanghee Kim Jonathan A. Coleman Tags: Article Source Type: research

Profiling of Androgen-Dependent Enhancer RNAs Expression in Human Prostate Tumors: Search for Malignancy Transition Markers
CONCLUSION: Presented data suggest that prostate tumor development may associate with epigenetic reorganization in the KLK3 genomic regulatory elements reflected by changes of the KLK3eRNA expression. Our findings support a potential of eRNAs profiling to be used as diagnostic marker.PMID:34549035 | PMC:PMC8449685 | DOI:10.2147/RRU.S328661
Source: Cell Research - September 22, 2021 Category: Cytology Authors: Koichi Nishimura Jinichi Mori Takahiro Sawada Shuhei Nomura Alexander Kouzmenko Kaori Yamashita Yoshiaki Kanemoto Tomohiro Kurokawa Akira Hayakawa Suguru Tokiwa Michihisa Ochi Hiroaki Shimmura Shigeaki Kato Source Type: research

Two cases of vascular complications after urologic robotic surgery
Acta Chir Belg. 2021 Dec 24:1-5. Online ahead of print.ABSTRACTPeripheral arterial disease (PAD) of the lower extremity is common and includes aortoiliac occlusive disease (AIOD) [1, 2]. Moreover, prostate cancer is the most common cancer in men [4] and is now treated with surgical robotic-assisted procedures [8]. This paper overviews two cases of limb ischemia after robotic-assisted radical prostatectomy (RARP) and their resolution. During both RARP, limb ischemia occurred due to the robotic instrument compressing the modified vascular structure. Indeed, in the surgical history of the concerned patients, one was treated b...
Source: Acta Chirurgica Belgica - December 24, 2021 Category: Surgery Authors: Charles-Edouard Gielen Yves Pignez Charles Swaelens Source Type: research

IJERPH, Vol. 19, Pages 2268: Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study
This study aimed to evaluate the effect of androgen deprivation therapy (ADT) on retinal vascular occlusion (RVO) development in patients with prostate cancer, using data from Taiwan’s National Health Insurance Research Database. A total of 1791, 1791, and 3582 patients were enrolled in the prostate cancer with ADT group, prostate cancer without ADT group, and the control group, respectively. The primary outcome was RVO occurrence, according to diagnostic codes. Cox proportional hazard regression was used to determine the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of ADT and other covariates...
Source: International Journal of Environmental Research and Public Health - February 17, 2022 Category: Environmental Health Authors: Hsin-Le Lin Chia-Yi Lee Jing-Yang Huang Po-Chen Tseng Shun-Fa Yang Tags: Article Source Type: research